Is Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) a Buy? The Stock Reported Less Sellers

September 17, 2017 - By Stephen Andrade

 Is Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) a Buy? The Stock Reported Less Sellers

The stock of Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) registered a decrease of 12.08% in short interest. CATB’s total short interest was 712,500 shares in September as published by FINRA. Its down 12.08% from 810,400 shares, reported previously. With 190,400 shares average volume, it will take short sellers 4 days to cover their CATB’s short positions. The short interest to Catabasis Pharmaceuticals Incorporated’s float is 6.81%.

The stock increased 0.60% or $0.01 on September 15, reaching $1.69. About 943,837 shares traded or 137.46% up from the average. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has declined 73.74% since September 17, 2016 and is downtrending. It has underperformed by 90.44% the S&P500.

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $37.99 million. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted , a linker drug discovery platform. It currently has negative earnings. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Ratings Coverage

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 10 analyst reports since August 17, 2015 according to SRatingsIntel. Wedbush maintained the stock with “Outperform” rating in Wednesday, June 8 report. The company was initiated on Thursday, December 22 by H.C. Wainwright. The firm has “Buy” rating by Citigroup given on Thursday, June 9. The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has “Buy” rating given on Monday, August 17 by Wedbush. The firm has “Buy” rating given on Monday, August 14 by H.C. Wainwright. The rating was maintained by Cowen & Co on Thursday, August 10 with “Hold”. The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has “Buy” rating given on Monday, August 14 by Wedbush. The rating was maintained by Oppenheimer on Monday, August 14 with “Buy”. On Tuesday, March 22 the stock rating was maintained by Citigroup with “Buy”.

More notable recent Catabasis Pharmaceuticals Inc (NASDAQ:CATB) news were published by: Businesswire.com which released: “Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD” on January 31, 2017, also Seekingalpha.com with their article: “Catabasis Pharmaceuticals Could Be A Strong Investment Opportunity In 2017” published on April 12, 2017, Seekingalpha.com published: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q1 2017 Results – Earnings …” on May 12, 2017. More interesting news about Catabasis Pharmaceuticals Inc (NASDAQ:CATB) were released by: Businesswire.com and their article: “Catabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference” published on August 09, 2017 as well as Businesswire.com‘s news article titled: “Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference” with publication date: June 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.